Nanoparticle-Based Vaccine Delivery for Cancer Immunotherapy
Immune Network 2013³â 13±Ç 5È£ p.177 ~ p.183
¹Ú¿µ¹Î(Park Yeong-Min) - Konkuk University School of Medicine Department of Immunology
À̽ÂÁØ(Lee Seung-Jun) - Konkuk University School of Medicine Department of Immunology
±è¿µ¼·(Kim Young-Seob) - Konkuk University School of Medicine Department of Immunology
À̹®Èñ(Lee Moon-Hee) - Konkuk University School of Medicine Department of Immunology
Â÷±æ¼±(Cha Gil-Sun) - Konkuk University School of Medicine Department of Immunology
Á¤Àδö(Jung In-Duk) - Konkuk University School of Medicine Department of Immunology
°ÅÂÈï(Kang Tae-Heung) - Konkuk University School of Medicine Department of Immunology
ÇÑÈñµ¿(Han Hee-Dong) - Konkuk University School of Medicine Department of Immunology
Abstract
Development of nano-sized carriers including nanoparticles, nanoemulsions or liposomes holds great potential for ad-vanced delivery systems for cancer immunotherapy, as such nanostructures can be used to more effectively manipulate or deliver immunologically active components to specific target sites. Successful development of nanotechnology based platform in the field of immunotherapy will allow the applica-tion of vaccines, adjuvants and immunomodulatory drugs that improve clinical outcomes for immunological diseases. Here, we review current nanoparticle-based platforms in the efficacious delivery of vaccines in cancer immunotherapy.
Å°¿öµå
Nanoparticle, Cancer, Vaccine, Immunotherapy
KMID :
0923620130130050177
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Nanoparticle-based delivery strategy has broad potential as a delivery platform in human disease and could be adapted for other presently incurable diseases.